

1/63




FIG. 1A




FIG. 1B




FIG. 2

3/63




FIG. 3A




FIG. 3B

4/63




FIG. 3C

5/63




FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D

-  Group 1: Vehicle Control
-  Group 2: Ab7 (25mg/kg)
-  Group 3: Ab1 (25mg/kg)
-  Group 4: Ab8 (25mg/kg)
-  Group 5: Ab9 (25mg/kg)

8/63




FIG. 8A




FIG. 8B






FIG. 8C

-  Group 1: Vehicle Control
-  Group 2: Ab7 (25mg/kg)
-  Group 3: Ab1 (25mg/kg)
-  Group 4: Ab8 (25mg/kg)
-  Group 5: Ab9 (25mg/kg)

9/63



10/63




FIG. 10B

FIG. 10A




FIG. 10D

FIG. 10C

12/63




FIG. 11A

FIG. 11B

13/63




FIG. 12B

FIG. 12A




FIG. 12D

FIG. 12C




FIG. 13B




FIG. 13A




FIG. 14B




FIG. 14A





FIG. 14C

FIG. 14D






FIG. 16B





FIG. 16A






FIG. 18A

PBS_Control
IgG_Ctl
Ab1
Ab2
Ab4
Ab6




FIG. 18B

Muscle	Ab	PBS_Ctl	20 mg/kg/wk	2 mg/kg/wk	0.5 mg/kg/wk
Gastrocnemius	Ab1	0	25.1	13.0	14.9
Gastrocnemius	Ab2	0	25.6	24.0	9.8
Gastrocnemius	Ab4	0	25.0	15.0	3.1
Gastrocnemius	Ab6	0	24.8	9.3	7.4
Quadriceps	Ab1	0	23.9	13.9	10.8
Quadriceps	Ab2	0	23.9	26.1	7.6
Quadriceps	Ab4	0	37.8	6.4	0.2
Quadriceps	Ab6	0	32.0	0.4	0.2

FIG. 18C




FIG. 19




FIG. 20

1 QVQLVESGGGVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY 60
61 ADSSVKGRFTISRDN SKNTLYLQMNSLRAEDAVYYCARDLLVRFLEWSHYYGMDVWGQGT 120
121 TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP 180
181 AVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDPKPSNTKVDKRVESKYGPPCPPAPEF 240
241 LGGPSVFLFPPKPKDILMISRTPEVTCVVVDVSQEDDEVQFNWYVDGVEVHNAKTKPREE 300
301 QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPS 360
361 QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDK 420
421 SRWQEGNVFSCSV MHEALHNHYTQKSLSLGLG 452

FIG. 21A

1 QSVLTQPPSASGTPGQQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSCGVP 60
61 DRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVLGQPKAAPSVTL 120
121 FPPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSSPVKAGVETTTPSKQSNKNKYAASSY 180
181 LSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS 215

FIG. 21B




FIG. 22

27/63




FIG. 23A





FIG. 23B



Top 12 clones selected for further characterization

Ab1:	4.8	nM		
Ab4:	0.47	nM	10-fold improved	
Ab6:	0.48	nM	10-fold improved	
Best affy matured mAb:	<10	pM	>480-fold improvement	

FIG. 23C

29/63

	FRAMEWORK 1	CDR1	FRAMEWORK 2
Ab1	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>GFTFSSYGMH</u>	WVRQAPGKGLEWVA
Ab3	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>GFAFSSYGMH</u>	WVRQAPGKGLEWVA
Ab5	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>GFAFSSYGMH</u>	WVRQAPGKGLEWVA

	CDR2	FRAMEWORK 3
Ab1	<u>VISYDGS</u> NKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	
Ab3	<u>VISYDGS</u> IKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	
Ab5	<u>VISYDGS</u> NKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	

	CDR3	FRAMEWORK 4
Ab1	<u>DLLVRFLEWSHY</u> YGMDVWGQGT TVTVSS	
Ab3	<u>DLLVRFLEWSH</u> YKYGMDVWGQGT TVTVSS	
Ab5	<u>DLLVRFLEWSH</u> YKYGMDVWGQGT TVTVSS	

FIG. 24A

	FRAMEWORK 1	CDR1	FRW2
Ab1	QPVL TQPPSASGTPGQ RVTISCSGSS	<u>SSNIGSNT</u>	VHWHYQQLPGTAPKLLIY
Ab3	QPVL TQPPSASGTPGQ RVTISCSGST	<u>SNIGSNT</u>	VHWHYQQLPGTAPKLLIY
Ab5	QPVL TQPPSASGTPGQ RVTISCSGSS	<u>SSNIGCNT</u>	VHWHYQQLPGTAPKLLIY

	CDR2	FRAMEWORK 3
Ab1	<u>SDNQRP</u> SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	
Ab3	<u>SDDQRP</u> SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	
Ab5	<u>SDDQRP</u> SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	

	CDR3	FRAMEWORK 4
Ab1	<u>AAWDDSLNGV</u> FGGGTKLTVL	
Ab3	<u>AAWDESLNGV</u> FGGGTKLTVL	
Ab5	<u>AAWDESLNGV</u> FGGGTKLTVL	

FIG. 24B

Myostatin Changes During Dexamethasone-Induced Muscle Atrophy




FIG. 25

Quantitation of Changes in Myostatin During Dexamethasone-Induced Muscle Atrophy
Fluorescent Western Blot (Azure Imager) - Normalized to Total Protein Loaded per Lane)




FIG. 26




FIG. 27

32/63




FIG. 28A





FIG. 28B



34/63

Ab2 Increases Muscle Mass in Sprague-Dawley Rats
10 mg/kg IV dose on Day 0




FIG. 30A




FIG. 30B

**Ab2 Treatment Increases Latent
But Not proMyostatin in Rat Muscle**
Quantitative Western - N=6 Samples/group




FIG. 31B

**Ab2 Treatment Increases
Latent Myostatin in Rat Serum**
Quantitative Western - N=3 Samples/group





FIG. 31A


36/63

***Increased Duration of Muscle Mass Gain in
Mice Treated with Ab2***

% Change in Lean Mass vs. Day 0
Measured by qNMR, N=4 to 8 per group

**FIG. 32**

37/63



	$t_{1/2}$ (day)	AUC_{INF} (day*ug/mL)
AbMyo	8.2	773
Ab2	20.3	2072

FIG. 33

38/63

***Ab2 and AbMyo Have Similar Effects
on Circulating Latent Myostatin***




FIG. 34

39/63

Muscle Latent Myostatin in Ab2 - and AbMyo - Treated Mice




FIG. 35A

Muscle proMyostatin in Ab2 - and AbMyo - Treated Mice




FIG. 35B

40/63




FIG. 36A




FIG. 36B




FIG. 37A




FIG. 37B




FIG. 37C




FIG. 37D




FIG. 37E




FIG. 37F




FIG. 37G




FIG. 37H




FIG. 38A




FIG. 38B




FIG. 38C




FIG. 38D

46/63




FIG. 38E




FIG. 38F




FIG. 38G




FIG. 38H




FIG. 38I

47/63

Ab10 DAPI




FIG. 39A

HuNeg DAPI




FIG. 39B

Supracellular localization of Myostatin precursors

α pro/latent Myostatin
+ 10x proGDF11




FIG. 40C

α pro/latent Myostatin
+ 10x proGDF8




FIG. 40B

α pro/latent Myostatin




FIG. 40A

Supracellular localization of Myostatin precursors




FIG. 41A

FIG. 41B

FIG. 41C




FIG. 42A




FIG. 42B




FIG. 43A




FIG. 43B




FIG. 43C




FIG. 43D

52/63




FIG. 44A




FIG. 44B

53/63

Readout	vehicle	Ab2 (3mpk)	Ab2 (10mpk)	Ab2 (30mpk)
Mean % change in lean mass @ 4 weeks	7.8	13.5	12.6	17.0
Mean % change in lean mass @ 8 weeks	10.0	16.8	14.5	17.9
Mean % change in lean mass @ 12 weeks	12.5	19.6	14.8	21.2
% difference in biceps weight vs. vehicle group	0.0	18.0	13.0	25.5
% difference in gastroc weight vs. vehicle group	0.0	21.7	16.0	22.9

FIG. 45

54/63




FIG. 46A




FIG. 46B




FIG. 47

56/63




FIG. 48




FIG. 49

58/63




FIG. 50




FIG. 51

60/63




FIG. 52




FIG. 53




FIG. 54

